ES2502691B1 - Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos - Google Patents

Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos Download PDF

Info

Publication number
ES2502691B1
ES2502691B1 ES201331394A ES201331394A ES2502691B1 ES 2502691 B1 ES2502691 B1 ES 2502691B1 ES 201331394 A ES201331394 A ES 201331394A ES 201331394 A ES201331394 A ES 201331394A ES 2502691 B1 ES2502691 B1 ES 2502691B1
Authority
ES
Spain
Prior art keywords
pharmaceutical
medical
applicable
stabilization method
protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES201331394A
Other languages
English (en)
Other versions
ES2502691A1 (es
Inventor
Teodoro MAYAYO FALO
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANI RED S L
SANI-RED SL
Original Assignee
SANI RED S L
SANI-RED SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to ES201331394A priority Critical patent/ES2502691B1/es
Application filed by SANI RED S L, SANI-RED SL filed Critical SANI RED S L
Priority to BR112015020658-1A priority patent/BR112015020658B1/pt
Priority to EP14830029.6A priority patent/EP3050894A4/en
Priority to CA2913394A priority patent/CA2913394A1/en
Priority to PCT/ES2014/000151 priority patent/WO2015011308A1/es
Priority to EP23175038.1A priority patent/EP4241783A1/en
Priority to KR1020157018008A priority patent/KR20160055720A/ko
Priority to CN201480028046.2A priority patent/CN105209476A/zh
Priority to MX2016001476A priority patent/MX2016001476A/es
Priority to JP2016544774A priority patent/JP6959002B2/ja
Priority to US14/759,320 priority patent/US20160030584A1/en
Priority to CN202311351237.XA priority patent/CN117402206A/zh
Priority to RU2016107313A priority patent/RU2642277C2/ru
Publication of ES2502691A1 publication Critical patent/ES2502691A1/es
Application granted granted Critical
Publication of ES2502691B1 publication Critical patent/ES2502691B1/es
Priority to US15/855,338 priority patent/US20180193467A1/en
Priority to US16/411,782 priority patent/US11147882B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1808—Epidermal growth factor [EGF] urogastrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos, particularmente factores de crecimiento celulares y/o proteínas como el factor de crecimiento epidérmico (EGF) y el factor de crecimiento fibroblástico (bFGF), que comprende una fase de dispersión, en condiciones normales de presión y temperatura, donde se realiza la incorporación de las proteínas en un medio anhidro constituido por componentes de carácter oleoso que presentan restos hidrófilos y garantizan las interacciones con las proteínas manteniendo su conformación en el estado nativo, siendo tales componentes aceite de pepita de uva, una base de varios componentes y butilhidroxitoluen.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6

Claims (1)

  1. imagen1
    imagen2
ES201331394A 2013-09-23 2013-09-25 Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos Active ES2502691B1 (es)

Priority Applications (15)

Application Number Priority Date Filing Date Title
ES201331394A ES2502691B1 (es) 2013-09-25 2013-09-25 Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
US14/759,320 US20160030584A1 (en) 2013-09-25 2014-09-23 Method for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products
CA2913394A CA2913394A1 (en) 2013-09-25 2014-09-23 Method for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products
PCT/ES2014/000151 WO2015011308A1 (es) 2013-09-25 2014-09-23 Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
EP23175038.1A EP4241783A1 (en) 2013-09-25 2014-09-23 Method for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products
KR1020157018008A KR20160055720A (ko) 2013-09-25 2014-09-23 위생제품, 의약품 및 화장품 제조에 활용될 수 있는 단백질 보존 및 안정화 방법
CN201480028046.2A CN105209476A (zh) 2013-09-25 2014-09-23 一种用于卫生制剂、医药及化妆品工业发展的保存和稳定蛋白质的方法
MX2016001476A MX2016001476A (es) 2013-09-25 2014-09-23 Metodo de conservacion y estabilizacion de proteinas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmaceuticos y cosmeticos.
BR112015020658-1A BR112015020658B1 (pt) 2013-09-25 2014-09-23 Método de conservação e estabilização de proteínas aplicável para desenvolvimentos industriais de formulações de produtos sanitários, farmacêuticos e cosméticos
EP14830029.6A EP3050894A4 (en) 2013-09-25 2014-09-23 Method for preserving and stabilising proteins, which can be used for industrial development of formulations of sanitary, pharmaceutical and cosmetic products
CN202311351237.XA CN117402206A (zh) 2013-09-25 2014-09-23 一种用于卫生制剂、医药及化妆品工业发展的保存和稳定蛋白质的方法
RU2016107313A RU2642277C2 (ru) 2013-09-25 2014-09-23 Способ сохранения и стабилизации протеинов
JP2016544774A JP6959002B2 (ja) 2013-09-25 2014-09-23 衛生、医薬、及び化粧製品製剤の産業発展のために適用可能な、タンパク質の保存及び安定化方法
US15/855,338 US20180193467A1 (en) 2013-09-25 2017-12-27 Method for preserving and stabilizing proteins for formulations of sanitary, pharmaceutical and cosmetic products
US16/411,782 US11147882B2 (en) 2013-09-23 2019-05-14 Method for preserving and stabilizing proteins for formulations of sanitary, pharmaceutical and cosmetic products

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES201331394A ES2502691B1 (es) 2013-09-25 2013-09-25 Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos

Publications (2)

Publication Number Publication Date
ES2502691A1 ES2502691A1 (es) 2014-10-03
ES2502691B1 true ES2502691B1 (es) 2015-07-07

Family

ID=51626311

Family Applications (1)

Application Number Title Priority Date Filing Date
ES201331394A Active ES2502691B1 (es) 2013-09-23 2013-09-25 Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos

Country Status (11)

Country Link
US (3) US20160030584A1 (es)
EP (2) EP3050894A4 (es)
JP (1) JP6959002B2 (es)
KR (1) KR20160055720A (es)
CN (2) CN105209476A (es)
BR (1) BR112015020658B1 (es)
CA (1) CA2913394A1 (es)
ES (1) ES2502691B1 (es)
MX (1) MX2016001476A (es)
RU (1) RU2642277C2 (es)
WO (1) WO2015011308A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105055265A (zh) * 2015-07-21 2015-11-18 北京博士园科技发展有限公司 一种美容养颜产品及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3998753A (en) * 1974-08-13 1976-12-21 Hoffmann-La Roche Inc. Water dispersible carotenoid preparations and processes thereof
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
US4806343A (en) * 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
US5416242A (en) * 1992-09-25 1995-05-16 Nippon Hypox Laboratories Incorporated Hydroquinone derivative
US6267985B1 (en) * 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
KR100366439B1 (ko) * 2000-02-21 2003-01-09 주식회사 대웅 상피세포 성장인자를 유효성분으로 하는 안정한 약제학적조성물
FR2814672B1 (fr) * 2000-10-03 2003-03-21 Oreal Composition cosmetique a phase continue lipophile comprenant un pigment goniochromatique multicouche et son utilisation en maquillage
MXPA03004883A (es) * 2000-12-01 2004-05-04 Battelle Memorial Institute Metodo para la estabilizacion de biomoleculas (por ejemplo, insulina) en formulaciones liquidas.
ES2232305B1 (es) * 2003-11-07 2006-07-16 Miguel Angel Palomo S.A. Procedimiento de obtencion de alimentos texturizados y termoestables a partir de materias primas naturales y productos obtenidos a partir del mismo.
US11039999B2 (en) * 2004-06-25 2021-06-22 Ferrosan Aps Compositions suitable for treating cutaneous signs of aging
US20080102128A1 (en) * 2006-07-28 2008-05-01 Flamel Technologies, Inc. Modified-release microparticles based on amphiphilic copolymer and on active principles(s) and pharmaceutical formulations comprising them
FR2910318B1 (fr) * 2006-12-20 2009-07-03 Flamel Technologies Sa Dispersion de polyaminoacides dans une phase lipidique continue.
ES2319061B1 (es) * 2007-09-11 2010-02-10 Biomedal, S.L. Metodo de conservacion de peptidos o proteinas.
US20110020519A1 (en) * 2008-01-04 2011-01-27 Aveka, Inc. Encapsulation of oxidatively unstable compounds
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
MX2011002836A (es) * 2008-09-17 2011-04-28 Chiasma Inc Composiciones farmaceúticas y métodos de administración relacionados.

Also Published As

Publication number Publication date
EP3050894A1 (en) 2016-08-03
US20180193467A1 (en) 2018-07-12
RU2016107313A (ru) 2017-09-04
KR20160055720A (ko) 2016-05-18
CN105209476A (zh) 2015-12-30
ES2502691A1 (es) 2014-10-03
BR112015020658B1 (pt) 2023-12-05
EP3050894A4 (en) 2017-04-19
MX2016001476A (es) 2016-07-12
CN117402206A (zh) 2024-01-16
US20160030584A1 (en) 2016-02-04
WO2015011308A1 (es) 2015-01-29
RU2642277C2 (ru) 2018-01-24
JP2017501206A (ja) 2017-01-12
EP4241783A1 (en) 2023-09-13
CA2913394A1 (en) 2015-01-29
BR112015020658A2 (pt) 2017-07-18
US11147882B2 (en) 2021-10-19
JP6959002B2 (ja) 2021-11-02
US20190290770A1 (en) 2019-09-26

Similar Documents

Publication Publication Date Title
BR112016000563A2 (pt) Método de preparar uma formulação farmacêutica, método de usar ácido hexanóico e/ou ácido cítrico ou pelo menos um sal dos mesmos, formulação farmacêutica e método de modular ou determinar respostas imunes relacionadas à administração de uma formulação farmacêutica
CY1119066T1 (el) Αναστολεις κρυσταλλικης βρωμο-περιοχης
CO2017005391A2 (es) Composiciones de antibiótico
CL2019000586A1 (es) Composiciones de toxinas clostridiales no proteicas.
CO2018005381A2 (es) Inhibidores éster de acc y usos de los mismos
CL2015003442A1 (es) Derivados heterociclicos
BR112016025504A2 (pt) composições para cuidado de lavanderia
UY35425A (es) Compuestos y sus usos en la modulación de la hemoglobina
AR093578A1 (es) Metodos para la elaboracion de polipeptidos procesados proteoliticamente
BR102013022698A8 (pt) Éster de poliglicerol, processo para a produção do mesmo, seu uso e formulação cosmética ou farmacêutica
UY35426A (es) Compuestos y sus usos en la modulación de la hemoglobina
ES2596248T3 (es) N-Carbamoilputrescina para mejorar la síntesis de proteínas musculares
CO2017000030A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
TR201910056T4 (tr) Göz sağlığına yönelik bileşim.
AR100608A1 (es) Complejos de citomegalovirus y usos de los mismos
AR085505A1 (es) Plantas que tienen modulados rasgos relacionados con el rendimiento y un metodo para producirlas
CO2017000056A2 (es) Moléculas que tienen cierta utilidad plaguicida e intermediarios, composiciones y procedimientos relacionados con las mismas
UY36248A (es) ?una dispersión a base de agua o aceite, formulaciones y método para prepararlas, y uso de las dispersiones o formulaciones?.
EA201390872A1 (ru) Оставляемые на коже после нанесения нетвердые улучшающие состояние кожи композиции, содержащие 12-гидроксистеариновую кислоту и этоксилированное гидрогенизированное касторовое масло
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
ES2502691B1 (es) Método de conservación y estabilización de proteínas, aplicable para desarrollos industriales de formulaciones de productos sanitarios, farmacéuticos y cosméticos
PE20160014A1 (es) Formulacion de una composicion sanguinea rica en plaquetas y/o factores de crecimiento, con proteinas gelificadas, y metodo de preparacion de la misma
ES2517741B1 (es) Composición para reducir y/o prevenir la caída del cabello y/o estimular su crecimiento
FR3063224B1 (fr) Emulsion huile-dans-eau comprenant un ester d’acide gras et de polyol, un alcool gras, une huile polaire et un acide organique
BR112014029874A8 (pt) composição farmacêutica do tipo emulsão óleo em água, composições e uso da composição farmacêutica

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 2502691

Country of ref document: ES

Kind code of ref document: B1

Effective date: 20150707